| Name | Title | Contact Details |
|---|
We are a leading Scientific Process Organization (SPO), providing scientific knowledge-based services to biopharmaceutical, generic pharmaceutical, consumer product, medical device, contract research and healthcare companies. We partner with our clients through the entire drug development cycle to provide a broad range of services from study design to post marketing surveillance and commercialization support. We deliver consistent quality and compliance across the services by employing scientific rigor in combination with streamlined process, optimal technology and efficient people practices.
Health Advocate, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Plymouth Meeting, PA. To find more information about Health Advocate, Inc., please visit www.healthadvocate.com
Wisteria Cottage is a Sequim, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Calypte Biomedical Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Portland, OR. To find more information about Calypte Biomedical Corporation, please visit www.calypte.com
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company`s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV. Bionor Pharma`s most advanced product candidate is Vacc-4x, which is also the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Pharma`s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through collaboration with Celgene, is investigating Vacc-4x and the HDAC inhibitor romidepsin in the REDUC study. In May 2015, Bionor Pharma announced promising results from an interim analysis of Part B of the REDUC study. In the study, Vacc-4x and romidepsin are explored as a possible treatment regimen to reduce the persistent latent viral reservoir in HIV infected patients on anti-retroviral treatment. Results are expected in the second half of 2015. Bionor Pharma is headquartered in Oslo, Norway, with offices in Copenhagen and New York.